Study guide

12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

Key Takeaways Explain This Topic AI

Levothyroxine replacement is generally indicated when TSH exceeds 10 mU/L, and in pregnancy the requirement rises by roughly 25-50% from early gestation.

Papillary thyroid carcinoma is the commonest type, spreads via lymphatics and has an excellent prognosis; medullary carcinoma arises from parafollicular C cells, secretes calcitonin and occurs in MEN2.

A raised TSH with a low free T4 indicates primary hypothyroidism, while a low or inappropriately normal TSH with a low free T4 indicates central (pituitary or hypothalamic) disease.

Last updated: September 2026

  • 4. Hypothyroidism & Subclinical Thyroid Dysfunction
  • Primary vs. Secondary (Central) Hypothyroidism

Primary Hypothyroidism: Elevated serum TSH with decreased free T4. Commonest aetiology in iodine-sufficient countries is Hashimoto's thyroiditis (autoimmune lymphocytic destruction, high anti-TPO titres, associated with other autoimmune diseases and a 40- to 60-fold increased risk of primary thyroid lymphoma ).

Secondary / Central Hypothyroidism: Inappropriately low or normal serum TSH in the presence of a low free T4. Results from pituitary pathology (macroadenoma, Sheehan's syndrome, lymphocytic hypophysitis) or hypothalamic disease. Critical Rule: In central hypothyroidism, always evaluate the hypothalamic-pituitary-adrenal (HPA) axis and treat adrenal insufficiency with hydrocortisone BEFORE initiating levothyroxine ; thyroxine accelerates hepatic cortisol clearance and precipitates fatal acute Addisonian crisis.

Levothyroxine Pharmacotherapy & Target Monitoring

Pure synthetic thyroxine (T4); half-life ~7 days. Administer on an empty stomach with water 30–60 minutes before breakfast (absorption impaired by iron, calcium, aluminium antacids, proton pump inhibitors, and dietary fibre).

Standard Adult Dose: ∼ 1.6 mcg/kg/day \sim 1.6\text{ mcg/kg/day} ∼ 1.6 mcg/kg/day (usually 100 – 125 mcg/day 100\text{–}125\text{ mcg/day} 100 – 125 mcg/day ). Target: normalization of serum TSH ( 0.5 – 2.5 mU/L 0.5\text{–}2.5\text{ mU/L} 0.5 – 2.5 mU/L ).

Ischaemic Heart Disease / Frail Elderly: Start at a low dose of 25 mcg once daily 25\text{ mcg once daily} 25 mcg once daily , titrating upwards slowly by 25 mcg increments every 4–6 weeks to prevent unmasking angina or precipitating myocardial infarction/arrhythmias.

Pregnancy Requirements: Fetal brain development is completely dependent on maternal transplacental T4 during the first trimester (fetal thyroid begins synthesis at 12–14 weeks). Oestrogen elevates thyroxine-binding globulin (TBG) and placental deiodinases increase T4 clearance. Women with established hypothyroidism must increase their levothyroxine dose by 25–50% (typically 2 extra tablets per week) immediately upon confirming pregnancy, targeting a first-trimester TSH < 2.5 mU/L < 2.5\text{ mU/L} < 2.5 mU/L with 4-weekly TSH surveillance.

Myxoedema Coma: Decompensated end-stage hypothyroidism presenting with hypothermia ( < 35 ∘ C < 35^\circ\text{C} < 3 5 ∘ C ), bradycardia, hypoventilation, hyponatraemia, hypotension, and obtundation. Emergency management: IV hydrocortisone 100 mg (prior to thyroid hormone), IV levothyroxine loading ( 200 – 400 mcg 200\text{–}400\text{ mcg} 200 – 400 mcg ) or IV liothyronine (T3), slow passive rewarming (avoid active external rewarming: precipitates peripheral vasodilation and shock), and supportive mechanical ventilation.

Subclinical Thyroid Disease

Subclinical Hypothyroidism: Elevated TSH with normal free T4 and free T3.

Indications to Treat (NICE Guidelines):

Serum TSH ≥ 10.0 mU/L \text{TSH} \ge 10.0\text{ mU/L} TSH ≥ 10.0 mU/L (high rate of progression to overt disease; adverse cardiovascular and lipid risk).

Serum TSH 5.5 – 10.0 mU/L \text{TSH } 5.5\text{–}10.0\text{ mU/L} TSH 5.5 – 10.0 mU/L in patients aged < 65 < 65 < 65 years with persistent hypothyroid symptoms, positive anti-TPO antibodies, or pregnant/planning conception.

In asymptomatic elderly patients ( > 80 > 80 > 80 years), conservative observation ("watch and wait") is recommended; treatment does not improve clinical outcomes and increases the risk of atrial fibrillation and bone demineralisation.

Subclinical Hyperthyroidism: Suppressed TSH ( < 0.1 mU/L < 0.1\text{ mU/L} < 0.1 mU/L ) with normal free T4 and free T3. Carries a 3-fold increased risk of atrial fibrillation and accelerated osteoporosis (loss of trabecular and cortical bone density). Treat with antithyroid drugs or radioiodine if TSH < 0.1 mU/L \text{TSH} < 0.1\text{ mU/L} TSH < 0.1 mU/L and age ≥ 65 \ge 65 ≥ 65 years, or presence of established cardiac disease, osteoporosis, or high fracture risk.

  • 5. Thyroid Nodules & Malignancies
  • Ultrasound Stratification: British Thyroid Association (BTA U1–U5)

U1 (Normal): No focal lesions.

U2 (Benign): Purely cystic, spongiform/honeycomb, hyperechoic nodule with peripheral halo.

U3 (Indeterminate): Equivocal solid features without high-risk signs.

U4 (Suspicious): Solid, hypoechoic, lobulated margin, microcalcifications.

U5 (Malignant): Marked hypoechogenicity, taller-than-wide shape, irregular/infiltrative margins, microcalcifications, disrupted rim calcification, abnormal cervical lymphadenopathy. Fine-needle aspiration cytology (FNAC) is indicated for U3–U5 lesions.

Primary Thyroid Malignancies: Histopathological & Clinical Classification Thyroid Malignancy Spectrum:

- Differentiated Epithelial:

• Papillary Carcinoma (~80%): BRAF / RET-PTC → Psammoma bodies, Orphan Annie nuclei → Lymphatic spread → Excellent prognosis

• Follicular Carcinoma (~10%): RAS / PAX8-PPARg → Requires capsular/vascular invasion → Haematogenous spread (bone/lung)

- Neuroendocrine C-Cell:

• Medullary Carcinoma (~5%): RET proto-oncogene (MEN 2A/2B) → Calcitonin / Amyloid stroma → Screen for phaeochromocytoma!

- Undifferentiated:

• Anaplastic Carcinoma (<2%): p53 mutations, elderly → Rapidly enlarging, compressive, highly aggressive → Dismal prognosis

- Lymphoid:

• Thyroid Lymphoma (<2%): Hashimoto's thyroiditis background → CD20+ B-cell lymphoma → Chemo/radiotherapy responsive

Papillary Thyroid Carcinoma (PTC): Most prevalent thyroid cancer ( 70 – 80 % 70\text{–}80\% 70 – 80% ). Associated with prior childhood head/neck radiation exposure and BRAF V600E mutations. Pathognomonic histology: Psammoma bodies (concentric lamellated calcospherites), Orphan Annie eye nuclei (large, pale, ground-glass cleared nuclei), and nuclear grooves. Spreads primarily via lymphatic drainage to regional cervical lymph nodes. Overall 20-year survival exceeds 90 – 95 % 90\text{–}95\% 90 – 95% . Management: total thyroidectomy, central compartment node dissection, postoperative radioiodine ( 131 I ^{131}\text{I} 131 I ) ablation, and suppressive levothyroxine; serum thyroglobulin is the primary tumour marker for recurrence surveillance.

Follicular Thyroid Carcinoma (FTC): Second most common ( 10 – 15 % 10\text{–}15\% 10 – 15% ). More frequent in iodine-deficient regions; linked to RAS mutations and PAX8-PPAR γ \gamma γ translocations. Crucial Diagnostic Rule: FNAC cannot differentiate a benign follicular adenoma from follicular carcinoma because cytologic features are identical. Histological proof of capsular invasion or vascular invasion on permanent surgical histology is strictly required to establish malignancy. Spreads primarily via haematogenous dissemination to bones (osteolytic metastases) and lungs. Treated with total thyroidectomy, radioiodine ablation, and thyroglobulin monitoring.

Medullary Thyroid Carcinoma (MTC): Neuroendocrine malignancy derived from calcitonin-secreting parafollicular C cells (neural crest origin). Accounts for ~5% of thyroid cancers. 75% sporadic; 25% familial as part of MEN 2A, MEN 2B , or familial MTC driven by germline activating missense mutations in the RET proto-oncogene on chromosome 10. Pre-Surgical Safety Rule: Must screen for phaeochromocytoma (plasma/urinary metanephrines) and primary hyperparathyroidism prior to neck surgery; if a phaeochromocytoma is detected, it must be resected first to prevent fatal intraoperative hypertensive crisis. Histology: sheets of neuroendocrine cells in dense stroma containing amyloid deposits (derived from procalcitonin; stains with Congo red, displaying apple-green birefringence under polarized light). Tumour markers: calcitonin and carcinoembryonic antigen (CEA) . Does NOT concentrate iodine; radioiodine-131 is completely ineffective.

Anaplastic Thyroid Carcinoma (ATC): Highly aggressive, undifferentiated tumour occurring almost exclusively in elderly patients ( > 65 > 65 > 65 years). Features inactivating mutations in TP53 . Presents as a rapidly expanding, stony-hard, fixed neck mass causing acute local invasion: stridor, dysphagia, and recurrent laryngeal nerve palsy (hoarseness). Histology reveals pleomorphic spindle and giant cells with extensive necrosis. Median survival is 3 to 6 months; therapy is largely palliative (airway protection, external beam radiation, targeted BRAF inhibitors like dabrafenib/trametinib if BRAF -mutated).

Primary Thyroid Lymphoma: Predominantly diffuse large B-cell lymphoma (DLBCL) or MALT lymphoma. Arises almost exclusively in the background of chronic autoimmune Hashimoto's thyroiditis (40- to 60-fold increased relative risk). Presents as a rapidly enlarging goitre with compressive symptoms in an elderly woman with known Hashimoto's. Core needle or surgical biopsy reveals dense sheets of CD20+ atypical lymphoid cells. Highly sensitive to systemic chemotherapy (CHOP) and radiotherapy; surgery is rarely indicated.